Susana Otero Romero - Institutions of which they are part Head of group Epidemiology and Public Health Vall Hebron Institut de Recerca Allergology General Hospital Email Susana Otero Romero Email Institutions of which they are part Head of group Epidemiology and Public Health Vall Hebron Institut de Recerca Allergology General Hospital -
Research lines Clinical epidemiology of Multiple Sclerosis To characterize the epidemiology of multiple sclerosis (MS) in Catalonia, a prospective registry of new cases of MS in Catalonia was set up in 2009 with the participation of 21 hospitals throughout Catalonia. Prevalence and incidence studies based on this population-based registry are being performed. Recently, and in collaboration with the Center of Multiple Sclerosis of Catalonia (Cemcat), we have set up a prospective registry of vaccination in patients with Immuno-Mediated Inflammatory Disease (IMID) who are candidates for biological treatment with the aim of evaluating vaccine immunogenicity and safety that will allow establishing the best vaccination strategy. In addition, we will study the prevalence and impact of comorbidity on Multiple Sclerosis prognosis. IP: Susana Otero Romero Projects Caracterización de las infecciones y de su impacto en pacientes con Esclerosis Múltiple en la era de los tratamientos inmunosupresores de alta eficacia IP: Susana Otero Romero Collaborators: Imane Boutitah Benyaich, Blanca Borras Bermejo, Anna Falcó Roget, Mar Tintore Subirana, Ana Zabalza de Torres, Jesus Trejo Zahinos, Enrique Rodríguez Zafra Funding agency: Instituto de Salud Carlos III Funding: 115000 Reference: PI23/01654 Duration: 01/01/2024 - 31/12/2026 TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027 DRIVE IP: Susana Otero Romero Collaborators: Eva del Amo Moran, Constanza Olivares Castillo Funding agency: The Innovative Medicines Initiative Funding: 130847.5 Reference: DRIVE_IMI2-2021 Duration: 01/10/2021 - 30/09/2022 Measuring brand-specific influenza vaccine effectiveness IP: Susana Otero Romero Collaborators: Eva del Amo Moran, Magda Campins Martí, Cristina Andrés Vergés Funding agency: The Innovative Medicines Initiative Funding: 75438 Reference: DRIVE_IMI2-2020_SUBART11 Duration: 20/07/2020 - 30/09/2021 Pagination Current page 1 Page 2 Page 3 Page 4 Next page › Last page »
